Celyad Oncology S.A. Celyad Oncology S.A.

Celyad Oncology S.A.

CYAD

Rank in Stocks #29398
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Share Price
$0.16500743
Last synced: 2026-11-17
Market Cap
$7.39M
Change (1 day)
6.90%
Change (1 year)
-23.37%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Celyad Oncology S.A. (CYAD)
Operating Margin as of November 2026 TTM: -68,728.57%
According to Celyad Oncology S.A.'s latest financial reports, its current operating margin (TTM) is -68,728.57%. At the end of 2025 the company had an operating margin of -34,200.00%.
Operating Margin history for Celyad Oncology S.A. from 2010 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -68,728.57% 100.96%
2025 -34,200.00% 916.33%
2024 -3,365.05% -67.61%
2023 -10,389.22% 0.00%
2022 0.00% 0.00%
2021 0.00% -100.00%
2020 -339,740.00% -29.41%
2019 -481,316.67% 39,179.61%
2018 -1,225.36% -17.96%
2017 -1,493.67% 483.97%
2016 -255.78% -99.97%
2015 -989,066.67% 8,685.28%
2014 -11,258.22% 0.00%
2013 0.00% -100.00%
2012 -2,668.52% -92.09%
2011 -33,725.68% 5,769.42%
2010 -574.60% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
33.87% -100.00%
US
-116.04% -100.00%
US
25.57% -100.00%
AU
29.35% -100.00%
NL
31.23% -100.00%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Celyad Oncology S.A.'s operating margin

What is Celyad Oncology S.A.'s operating margin?

Celyad Oncology S.A.'s operating margin is -68,728.57%, as of Nov 2026.

What was Celyad Oncology S.A.'s operating margin in 2025?

In 2025, Celyad Oncology S.A.'s operating margin was -34,200.00%, compared with -3,365.05% in 2024.

How has Celyad Oncology S.A.'s operating margin changed since 2020?

From 2020 to 2025, Celyad Oncology S.A.'s operating margin was highest in 2022 (0.00%) and lowest in 2020 (-339,740.00%).

How does Celyad Oncology S.A.'s operating margin compare with similar companies?

Celyad Oncology S.A.'s operating margin (-68,728.57%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.